Comera Life Sciences Holdings, Inc. (CMRA) Stock Price, Financial Report, & Fundamental Analysis

Strength

Analysis	#
Price to Book (PBV) Ratio Undervalued price-to-book. CMRA stock price is under 1x the price-to-book value.
Debt-Equity Ratio (DER) CMRA equity is higher than it's debt.
Return of Equity CMRA has GREAT return of equity (286.02%).
Revenue CMRA has positive revenue for last 2 years

Weakness

Analysis	#
Market Cap Small market capitalization. Market capitalization is less than 2bn USD
Revenue Growth CMRA has never had growing revenue.
Net Income Growth CMRA has never had growing net income.
Net Income CMRA never has positive net income for 2 years.
Dividend Yield CMRA has low dividend yield (0%).
Return of Assets CMRA has low return of asset (-323.17%).
Return of Invested Capital CMRA has low ROIC.

Competitors

Financial statements are written records that convey the business activities and the financial performance of a company. Financial statements include the balance sheet, income statement, and statement of cash flow.

Income Statement

Also known as the profit and loss (P&L) statement or the statement of revenue and expense, the income statement primarily focuses on the company’s revenue and expenses during a particular period.

Cashflow Statement

A cash flow statement is a financial statement that provides aggregate data regarding all cash inflows a company receives from its ongoing operations and external investment sources. It also includes all cash outflows that pay for business activities and investments during a given period.

Free Cash Flow

-3,899,962 USD

Dividend

Financial Ratios

CEO

CEO Name

Mr. Jeffrey S. Hackman

Management

About Comera Life Sciences Holdings, Inc.

Comera Life Sciences Holdings, Inc., a preclinical stage life sciences company, develops an internal portfolio of proprietary therapeutics that incorporate its proprietary formulation platform, SQore. Its SQore platform is designed to enable the conversion of intravenous (IV) biologics to subcutaneous (SQ) versions. The company is advancing its primary product programs, CLS-001, a preclinical stage biobetter for Crohn's and Ulcerative Colitis disease, and CLS-002, a preclinical stage biobetter for various oncology indications. Comera Life Sciences Holdings, Inc. was founded in 2014 and is headquartered in Woburn, Massachusetts.

Additional Information

Company name

Comera Life Sciences Holdings, Inc.

Symbol

NASDAQ:CMRA

Exchange

NASDAQ Capital Market

Industry

Biotechnology

Sector

Healthcare

Address

12 Gill Street
Woburn
MA
US
01801

Website

https://comeralifesciences.com